Annals of the Rheumatic Diseases
Издатель: Elsevier · ISSN 0003-4967 · 86 статей
- Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups
- Broad screening of inflammation-associated proteins identifies serum CCL19 as a novel biomarker of disease activity in IgG4-related disease
- Longitudinal profiling reveals immune dynamics and distinct plasma cell signatures during B-cell depletion in IgG4-related disease
- Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions for disease elements in calcium pyrophosphate crystal deposition (CPPD)
- A novel STAT4 gain-of-function variant defines a monogenic form of juvenile-onset systemic lupus erythematosus
- Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma
- Correspondence on ‘Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis—a case series’ by Siegert et al
- Response to a Correspondence on ‘Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis – a case series’
- Correspondence on ‘Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials’ by Annfeldt et al
- Response to correspondence on ‘Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials’ by Annfeldt et al
- Correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Looijen et al
- Response to correspondence on ‘Development and validation of a model to predict the disease activity score: towards a remote treat-to-target approach for rheumatoid arthritis’ by Zhang et al
- Correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’ by Imai et al
- Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’
- Corrigendum to Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: A target trial emulation study Ann Rheum Dis 2025;84(11):1938-1947
- Corrigendum to EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia Ann Rheum Dis. 2025 Sep;84(9):1445-1457. doi: 10.1016/j.ard.2025.01.021. Epub 2025 May 8
- Nicotinamide N-methyltransferase drives fibroblast activation and skin fibrosis in systemic sclerosis
- The impact of HFE genotypes and iron loading on joint disease: evidence for HFE-associated arthropathy without genetic haemochromatosis
- Global burden and economic cost of musculoskeletal disorders in the working-age population, 1990-2023
- Blinatumomab in dermatomyositis and refractory ANCA-associated vasculitis: a 2-patient exploratory study
- Making sense of publicly available omics dataset
- Pharmaceutical blockade of the neonatal Fc receptor (FcRn) ameliorates autoimmunity, inflammation, and fibrosis in the antitopoisomerase-I antibody–driven mouse model of systemic sclerosis
- Validation of rheumatoid arthritis low inflammatory activity: a novel clinical target quantifying inflammatory disease activity
- ERN-RITA/PReS recommendations for the diagnosis, classification, monitoring, and treatment of childhood idiopathic (primary) angiitis of the central nervous system
- Shared and distinct inflammatory signatures in gout flare and acute CPP crystal arthritis: systemic inflammation persists in gout despite achieving serum urate target
- AI-supported screening for systematic literature reviews informing EULAR recommendations and points to consider